C. Craddock

发表

The role of allogeneic SCT in primary myelofibrosis: a British Society for Blood and Marrow Transplantation study

N. Russell, G. Cook, D. Marks, 2010, Bone Marrow Transplantation.

Evidence for a GVL effect following reduced-intensity allo-SCT in ALL: a British Society of Blood and Marrow Transplantation study

G. Cook, B. Shaw, T. Littlewood, 2013, Bone Marrow Transplantation.

Recommendations for a standard UK approach to incorporating umbilical cord blood into clinical transplantation practice: conditioning protocols and donor selection algorithms

N. Russell, S. Mackinnon, J. Madrigal, 2009, Bone Marrow Transplantation.

Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant

G. Mufti, N. Russell, J. Cavenagh, 2008, Bone Marrow Transplantation.

Greatly reduced risk of EBV reactivation in rituximab-experienced recipients of alemtuzumab-conditioned allogeneic HSCT

C. Craddock, P. Moss, S. Nagra, 2016, Bone Marrow Transplantation.

M. Labopin, I. Yakoub-Agha, D. Blaise, 2022, Bone marrow transplantation.

Allogeneic hematopoietic cell transplantation for patients with AML aged 70 years or older in first remission. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).

P. Chevallier, A. Nagler, M. Mohty, 2023, Bone marrow transplantation.

Pertussis: should we vaccinate post transplant?

F. Clark, C. Craddock, G. Kochethu, 2006, Bone Marrow Transplantation.

Immune haemolytic anaemia following T cell-depleted allogeneic bone marrow transplantation for chronic myeloid leukaemia: association with leukaemic relapse and treatment with donor lymphocyte infusions

C. Craddock, J. Goldman, F. Dazzi, 2001, Bone Marrow Transplantation.

Early reconstitution of effector memory CD4+ CMV-specific T cells protects against CMV reactivation following allogeneic SCT

C. Craddock, P. Moss, K. Piper, 2009, Bone Marrow Transplantation.

Impact of pre-transplant co-morbidities on outcome after alemtuzumab-based reduced intensity conditioning allo-SCT in elderly patients: A British Society of Blood and Marrow Transplantation study

C. Craddock, S. Nagra, E. Tholouli, 2015, Bone Marrow Transplantation.

Role of HCT-comorbidity index, age and disease status at transplantation in predicting survival and non-relapse mortality in patients with myelodysplasia and leukemia undergoing reduced-intensity-conditioning hemopoeitic progenitor cell transplantation

C. Craddock, S. Nagra, N. Russell, 2012, Bone Marrow Transplantation.

P O B O X 1 1 7 2 2 1 0 0 L U N D + 4 6 4 6 -2 2 2 0 0 0 0

J. Esteve, M. Labopin, I. Yakoub-Agha, 2022 .

Alemtuzumab markedly reduces chronic GVHD without affecting overall survival in reduced-intensity conditioning sibling allo-SCT for adults with AML

C. Craddock, R. Malladi, J. Cavenagh, 2009, Bone Marrow Transplantation.

Rituximab is effective in the management of refractory autoimmune cytopenias occurring after allogeneic stem cell transplantation

C. Craddock, A. Ho, P. Mahendra, 2005, Bone Marrow Transplantation.

University of Birmingham Allogeneic stem cell transplantation benefits for patients 60 years with acute myeloid leukemia and FLT3 internal tandem duplication:

J. Esteve, M. Labopin, P. Chevallier, 2018 .

Conditioning intensity in middle-aged patients with AML in first CR: no advantage for myeloablative regimens irrespective of the risk group–an observational analysis by the Acute Leukemia Working Party of the EBMT

C. Craddock, M. Labopin, P. Chevallier, 2015, Bone Marrow Transplantation.

Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells

A. Børresen-Dale, J. Esteve, C. Desmedt, 2017 .

Identification of Prognostic Factors Predicting the Outcome of Reduced Intensity Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma. An Analysis from the Lymphoma Working Party of the EBMT

N. Schmitz, C. Craddock, K. Peggs, 2008 .

M. Labopin, I. Yakoub-Agha, D. Blaise, 2023, Bone Marrow Transplantation.

Artificial intelligence methods to estimate overall mortality and non-relapse mortality following allogeneic HCT in the modern era: an EBMT-TCWP study.

U. Salmenniemi, E. Forcade, Z. Perić, 2023, Bone marrow transplantation.

Comparison of fludarabine/melphalan (FluMel) with fludarabine/melphalan/BCNU or thiotepa (FBM/FTM) in patients with AML in first complete remission undergoing allogeneic hematopoietic stem cell transplantation – a registry study on behalf of the EBMT Acute Leukemia Working Party

E. Tholouli, J. Snowden, J. Finke, 2023, Bone marrow transplantation.

EBV-associated post-transplant lymphoproliferative disorder following in vivo T-cell-depleted allogeneic transplantation: clinical features, viral load correlates and prognostic factors in the rituximab era

A. Pettitt, C. Craddock, J. Byrne, 2014, Bone Marrow Transplantation.

A comparative assessment of the curative potential of reduced intensity allografts in acute myeloid leukaemia

C. Craddock, R. Hills, L. Kjeldsen, 2014, Leukemia.

P O B O X 1 1 7 2 2 1 0 0 L U N D + 4 6 4 6 -2 2 2 0 0 0 0

J. Esteve, C. Craddock, M. Labopin, 2022 .

Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT

R. Porcher, G. Mufti, C. Craddock, 2017, Bone Marrow Transplantation.

The impact of center experience on results of reduced intensity: allogeneic hematopoietic SCT for AML. An analysis from the Acute Leukemia Working Party of the EBMT

G. Mufti, C. Craddock, M. Labopin, 2013, Bone Marrow Transplantation.